查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466051

镰状细胞性贫血检测和筛检市场：按技术、年龄层、产业划分 - 2024-2030 年全球预测

Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography, Point-of-Care Tests), Age Group, Sector - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

镰状细胞贫血检测和筛检市场规模预计到 2023 年为 9.4395 亿美元，2024 年达到 10.7069 亿美元，2030 年达到 22.9322 亿美元，预计复合年增长率为 13.51%。

镰状细胞性贫血，也称为镰状细胞疾病 (SCD)，是一种影响血红蛋白的遗传性疾病，血红蛋白是红血球中的分子，为全身细胞提供氧气。患有镰状贫血的人含有血红蛋白 S，它可以将红血球扭曲成镰状（新月）形状。这些镰状细胞很难流经血管，阻碍血液流向身体各部位，进而导致慢性疼痛、严重感染疾病和其他併发症。世界各地镰状细胞性贫血的盛行率不断增加，推动了检测和筛检解决方案的采用。此外，新兴国家医疗保健基础设施的扩张有助于扩大检测、筛检和服务的取得和普及。然而，基因检测的高成本和有限的报销政策可能会阻碍市场成长，特别是在低收入国家。此外，分子诊断和高通量筛检方法的创新正在简化测试过程，提高准确性并缩短週转时间。

主要市场统计
基准年[2023] 94395万美元
预测年份 [2024] 10.7069 亿美元
预测年份 [2030] 22,932.2 亿美元
复合年增长率（%） 13.51%

技术不断进步，特别是用于早期新生儿筛检的血红蛋白电泳

血红蛋白电泳是一种传统的实验室技术，广泛用于根据电荷和大小识别不同类型的血红蛋白。该测试旨在检测异常血红蛋白，这表明镰状细胞性贫血等疾病。当需要明确诊断时首选。等电聚焦 (IEF) 是一种专门的电泳方法，可在等电点 (pI) 处分离血红蛋白异型性，即分子不带净电荷的 pH 值。 IEF 通常用作醋酸纤维素或毛细管电泳初步筛检后的验证测试。高效液相层析(HPLC) 是一种强大的分析技术，用于定量和鑑定各种血红蛋白。 HPLC 由于其准确性和快速週转时间而经常用于镰状细胞疾病筛检。镰状细胞性贫血的 POCT（护理点测试）测试是一种设计用于在患者护理点或附近使用的诊断工具。 POCT 因其方便、快速以及能够在各种环境（包括资源有限的国家）中实现早期、轻鬆检测而受到重视。侧流免疫测量(LFIA) 是一种简单的便携式设备，旨在检测生物检体中是否存在特定分析物，例如蛋白质、病原体和分子标记。 LFIA 利用试纸条形式直观地指示血液样本中是否有镰状细胞血红素。纸本快速诊断是一种创新的 POC 测试方法，它利用了纸张的吸收特性。这种经济高效且用户友好的测试需要最少的检体量，并且可以在没有先进测试基础设施的区域成功使用。

Sector Company Labs 处于创新和技术的前沿，提供全面的服务。

企业实验室通常在诊断测试的开发和提供中发挥关键作用，包括用于检测镰状细胞性贫血的测试。此类实验室通常提供高通量测试能力并拥有广泛的研发资源。受到寻求最新、最全面测试选项的患者和医疗保健提供者的青睐。政府实验室通常由国家或地方政府卫生部门资助和营运。这些实验室对于公共卫生监测和疾病预防工作至关重要，例如新生儿筛检镰状贫血筛检计画。我们专注于为居民，特别是高风险社区的居民提供方便、补贴的服务。私人测试设施提供个人化测试服务，通常迎合需要隐私和快速结果的客户。这些测试设施范围从小型本地设施到大型高端设施。客户喜欢优质的客户服务、快速的周转时间以及自付费用或私人保险的能力。官民合作关係是利用私部门的效率和公共部门的可近性来改善医疗保健服务的合作。这种伙伴关係在资源有限和镰状贫血负担高的地区特别有效。 PPP 可以帮助扩大筛检计划并整合护理网络。

区域洞察

在美洲，消费者对准确、早期诊断、定期筛检的需求很高。这反映在已建立的新生儿筛检计画和工作中，例如疾病预防控制中心的镰状细胞新生儿筛检计画。这些地区的客户购买行为受到医疗保险政策和基因检测覆盖范围的影响。欧盟国家对镰状细胞性贫血的认知和筛检有所不同。镰状贫血较为流行的欧洲地区国家製定了更健全的筛检计画。欧洲血液学会是积极参与调查的组织之一。欧盟消费者对 SCA 测试的购买行为是受到医疗保健法规和国家医疗保健服务可用性的推动。由于镰状细胞贫血症的高盛行率，非洲的镰状贫血检测和筛检市场非常重要。对经济实惠且可用的 SCA 测试选项的需求不断增长。镰状细胞性贫血在日本和中国等东亚国家稍微流行，印度仍然是公共卫生问题。在印度，SCA筛检被纳入更广泛的健康活动中，特别是在部落地区。亚太地区的消费者需求各不相同，但对遗传疾病和早期检测益处的认识正在不断提高。

FPNV定位矩阵

FPNV 定位矩阵对于评估镰状贫血检测和筛检市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对镰状细胞性贫血测试和筛检市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.镰状贫血检测和筛检市场的市场规模和预测是多少？

2.在镰状细胞性贫血检测和筛检市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.镰状细胞贫血检测和筛检市场的技术趋势和法规结构是什么？

4.镰状细胞贫血检测和筛检市场主要供应商的市场占有率是多少？

5.进入镰状贫血检测和筛检市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 镰状疾病的全球盛行率
      • 政府继续努力支持诊断
      • 高效液相层析(HPLC) 检测镰状细胞疾病的重要用途
    • 抑制因素
      • 镰状贫血相关的诊断与治疗问题
    • 机会
      • 开发深度学习框架，旨在对镰状贫血进行自动筛检
      • 更重视开发非侵入式、便携式和数位技术
    • 任务
      • SCD 相关的临床异质性和併发症
      • 缺乏资源和熟练的临床实验室技术人员
  • 市场区隔分析
    • 技术：血红蛋白电泳的持续进步，尤其是早期新生儿筛检
    • 部门：企业实验室处于创新和技术的前沿，提供全面的服务。
  • 市场趋势分析
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化

第六章镰状细胞性贫血检测与筛检市场：依技术分类

  • 血红素电泳
  • 高效液相层析（HPLC）
  • 就地检验

第七章镰状状细胞性贫血检测与筛检市场：依年龄组

  • 成人筛检
  • 新生儿筛检
  • 第1年至第25年

镰状8 章依产业分類的镰状细胞性贫血检测与筛检市场

  • 企业实验室
  • 政府研究所
  • 私人实验室
  • 官民合作关係

第九章美洲镰状细胞性贫血检测与筛检市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区镰状细胞镰状检测与筛检市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲镰状细胞性贫血检测与筛检市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 授予 300 万美元用于将血压药物重新用于 SCD 的研究
    • Mylab 推出独特的照护现场快速镰状细胞贫血检测
    • Lord's Mark Industries 与印度理工学院孟买分校合作在印度推广镰状细胞检测

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-A339DAEFA37A

[185 Pages Report] The Sickle Cell Anemia Testing & Screening Market size was estimated at USD 943.95 million in 2023 and expected to reach USD 1,070.69 million in 2024, at a CAGR 13.51% to reach USD 2,293.22 million by 2030.

Sickle cell anemia, known as sickle cell disease (SCD), is a genetic disorder that affects hemoglobin, the molecule in RBCs that delivers oxygen to cells throughout the body. People with sickle cell anemia have hemoglobin S, which can warp red blood cells into a sickle, or crescent, shape. These sickled cells can cause chronic pain, serious infections, and other complications because they do not flow through blood vessels easily and can block blood flow to parts of the body. Increasing prevalence of sickle cell anemia across the globe driving the adoption of testing & screening solutions. In addition, expanding healthcare infrastructure in emerging economies supports greater access to and adoption of testing and screening services. However, the high cost of genetic testing and limited reimbursement policies can impede market growth, particularly in low-income countries. Furthermore, innovations in molecular diagnostics and high-throughput screening methods are streamlining the testing process, increasing its accuracy, and reducing turnaround times.

KEY MARKET STATISTICS
Base Year [2023] USD 943.95 million
Estimated Year [2024] USD 1,070.69 million
Forecast Year [2030] USD 2,293.22 million
CAGR (%) 13.51%

Technology: Ongoing advancements hemoglobin electrophoresis for initial screening particularly in newborns

Hemoglobin electrophoresis is a traditional testing technique widely used to identify different types of hemoglobin based on their electrical charge and size. This test aims to detect abnormal hemoglobin, which can indicate disorders, including sickle cell anemia. It's preferred in cases where definitive diagnosis is required. Isoelectric focusing (IEF) is a specialized form of electrophoresis that separates hemoglobin variants by their isoelectric point (pI), the pH at which a molecule carries no net charge. IEF is often used as a confirmatory test following initial screening with cellulose acetate or capillary electrophoresis. High-performance Liquid Chromatography (HPLC) is a powerful analytical technique employed for the quantification and identification of various hemoglobins. HPLC is frequently used for sickle cell disease screening due to its accuracy and rapid turnaround time. Point-of-care tests (POCT) for sickle cell anemia are diagnostic tools designed for use at or near the point of patient care. They are prized for their convenience, speed, and the ability to enable early and easy detection in a variety of settings, including countries with limited resources. Lateral flow immunoassays (LFIA) are simple, portable devices invented to detect the presence of specific analytes such as proteins, pathogens, and molecular markers in a biological sample. Utilizing a test strip format, LFIAs create a visual representation of the presence and absence of sickle cell hemoglobin in a blood sample. Paper-based rapid diagnostics are an innovative approach to POC testing that leverages the absorbent nature of paper to conduct assays. These cost-effective and user-friendly tests require minimal sample volume and can be adeptly employed in areas lacking advanced laboratory infrastructure.

Sector: Corporate labs are at the forefront of innovation and technology to provide comprehensive services

Corporate labs often play a significant role in the development and provision of diagnostic tests, including those used for the detection of sickle cell anemia. These labs typically offer high-throughput testing capabilities and have substantial research and development resources. They are preferred by patients and healthcare providers who are seeking the latest and most comprehensive testing options. Government labs are usually funded and operated by national or regional government health departments. These labs are crucial for public health surveillance and disease prevention efforts, including newborn screening programs for sickle cell anemia. They focus on providing accessible and subsidized services to the population, particularly targeting high-risk communities. Private labs provide personalized testing services and often cater to a clientele seeking privacy and expedited results. These labs can range from small-scale local facilities to large, high-end operations. Their preference is based on the quality of customer service, faster turnaround times, and the ability to pay out-of-pocket or through private insurance. Public-private partnerships are collaborations that leverage the efficiency of the private sector and the accessibility of the public sector to enhance healthcare services. These partnerships can be particularly effective in regions where resources are limited and the burden of sickle cell anemia is high. PPPs can serve to expand screening programs and integrate care networks.

Regional Insights

In the American region, there is a high consumer need for accurate and early diagnosis, as well as routine screening. This is reflected in established newborn screening programs and initiatives such as the Sickle Cell Disease Newborn Screening Program by the CDC. Customer purchasing behavior in these regions is influenced by healthcare insurance policies and coverage for genetic testing. The awareness and screening for sickle cell anemia vary across EU countries. Countries in the European region, where the disease is more prevalent, have more robust screening programs. The European Hematology Association is one organization actively engaging in research. The EU consumer purchasing behavior for SCA testing is motivated by healthcare regulations and the availability of national health services. The sickle cell anemia testing and screening market in Africa is significant due to the high prevalence of the disease. There is a growing demand for affordable and available testing options for SCA. Sickle cell anemia is slightly prevalent in East Asian countries such as Japan and China, corresponding to India, where it remains a public health concern. In India, SCA screening is incorporated into broader health initiatives, particularly in tribal regions. Consumer needs in the Asia Pacific region vary, but there is increasing awareness about genetic diseases and the benefits of early testing.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Sickle Cell Anemia Testing & Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sickle Cell Anemia Testing & Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Sickle Cell Anemia Testing & Screening Market, highlighting leading vendors and their innovative profiles. These include Agios Pharmaceuticals, Inc., Anamol Laboratories Pvt. Ltd., Atlas Medical GmbH, Bio Lab Diagnostics (I) Private Limited, Bio-Rad Laboratories, Inc., Biomedomics Inc., Bluebird bio, Inc., Calibre Scientific, Inc., CRISPR Therapeutics AG, Edvotek Inc., Hemex Health, HiMedia Laboratories, Laboratory Corporation of America Holdings, Maternova Inc., PerkinElmer, Inc., Pfizer Inc., PicnicHealth, Quest Diagnostics Incorporated, Silver Lake Research Corporation, Streck, Inc., Thermo Fisher Scientific Inc., Ulta Lab Tests, LLC, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Sickle Cell Anemia Testing & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Hemoglobin Electrophoresis
      • Isoelectric focusing
    • High-performance Liquid Chromatography (HPLC)
    • Point-of-Care Tests
      • Lateral Flow Immunoassay
      • Paper Based Rapid Diagnostics
  • Age Group
    • Adult Screening
    • Newborn Screening
    • Years 1 to 25
  • Sector
    • Corporate Labs
    • Government Labs
    • Private Labs
    • Public-Private-Partnerships
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Sickle Cell Anemia Testing & Screening Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sickle Cell Anemia Testing & Screening Market?

3. What are the technology trends and regulatory frameworks in the Sickle Cell Anemia Testing & Screening Market?

4. What is the market share of the leading vendors in the Sickle Cell Anemia Testing & Screening Market?

5. Which modes and strategic moves are suitable for entering the Sickle Cell Anemia Testing & Screening Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Sickle Cell Disease Worldwide
      • 5.1.1.2. Ongoing Government Initiatives to Support the Diagnosis
      • 5.1.1.3. Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
    • 5.1.2. Restraints
      • 5.1.2.1. Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
      • 5.1.3.2. Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Clinical Heterogeneity and Complications Associated with SCD
      • 5.1.4.2. Lack of Resources and Skilled Clinical Laboratory Workforce Shortages
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Ongoing advancements hemoglobin electrophoresis for initial screening particularly in newborns
    • 5.2.2. Sector: Corporate labs are at the forefront of innovation and technology to provide comprehensive services
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Sickle Cell Anemia Testing & Screening Market, by Technology

  • 6.1. Introduction
  • 6.2. Hemoglobin Electrophoresis
  • 6.3. High-performance Liquid Chromatography (HPLC)
  • 6.4. Point-of-Care Tests

7. Sickle Cell Anemia Testing & Screening Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adult Screening
  • 7.3. Newborn Screening
  • 7.4. Years 1 to 25

8. Sickle Cell Anemia Testing & Screening Market, by Sector

  • 8.1. Introduction
  • 8.2. Corporate Labs
  • 8.3. Government Labs
  • 8.4. Private Labs
  • 8.5. Public-Private-Partnerships

9. Americas Sickle Cell Anemia Testing & Screening Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Sickle Cell Anemia Testing & Screening Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Sickle Cell Anemia Testing & Screening Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. USD 3 million awarded to study repurposing of blood pressure drug for SCD
    • 12.3.2. Mylab introduces indigenous Point-of-care, Rapid Sickle Cell Anemia Test
    • 12.3.3. Lord's Mark Industries, IIT-Bombay partner to advance sickle cell testing in India

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET RESEARCH PROCESS
  • FIGURE 2. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SICKLE CELL ANEMIA TESTING & SCREENING MARKET DYNAMICS
  • FIGURE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ISOELECTRIC FOCUSING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ISOELECTRIC FOCUSING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PAPER BASED RAPID DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PAPER BASED RAPID DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ADULT SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ADULT SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY YEARS 1 TO 25, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY YEARS 1 TO 25, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CORPORATE LABS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CORPORATE LABS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC-PRIVATE-PARTNERSHIPS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC-PRIVATE-PARTNERSHIPS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 120. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 129. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 130. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 131. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 132. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 139. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 140. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 141. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 142. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 149. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 150. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 151. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 152. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 159. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 160. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 161. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 162. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 169. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 170. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 171. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 172. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 182. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 189. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 190. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 191. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 192. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 200. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 202. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 204. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 209. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 210. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 211. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 212. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 213. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 214. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 219. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 220. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 221. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 222. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 223. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 224. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 229. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 230. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 231. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 232. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 233. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 234. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 251. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 252. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 253. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 254. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 255. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 256. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 261. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 262. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 263. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 264. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 265. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 266. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 271. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 272. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 273. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
  • TABLE 274. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
  • TABLE 275. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
  • TABLE 276. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
  • TABLE 281. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 282. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 283. FRANCE SICKLE CELL ANEMIA TESTING & SC